Acadia Pharmaceuticals Inc ACAD
We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. 10-K, Item 1
- Headquarters
- San Diego, CA
- CEO
- Stephen R. Davis
- Next results
- around Jan 12, 2027
Where each dollar of revenue went, FY2025
Revenue of $1.1B through the costs to a net profit of $391.0M · income statement of the 10-K
ACAD among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
32 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 26, 2026 against Feb 27, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
2facts worth reading about the other 9 checks found nothing to note
-
Receivables growing faster than revenueReceivables +23.0% ($98.7M to $121.5M) vs revenue +11.9% ($957.8M to $1.1B), +11.1 pts apart
-
Cash from operations lower than net incomeCash from operations $109.8M vs net income $391.0M (FY ending Dec 31, 2025)
-
Inventory +21.5% ($91.7M to $111.4M) vs revenue +11.9% ($957.8M to $1.1B), +9.6 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Medicare Part D sales rebate accruals
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
32 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
The process of obtaining regulatory approval of medicinal products in the EU and elsewhere, is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects. We operate in a global economy, and our business depends on a global supply chain for the development, manufacturing, and distribution of our pharmaceutical products,…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
For example, on July 4, 2025, the OBBBA was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance.…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
An expansion in the government’s role in the U.S. healthcare industry may increase existing congressional or governmental agency scrutiny on price increases, such as the ones we have implemented for NUPLAZID, cause general downward pressure on the prices of prescription drug products, lower reimbursements for providers using our…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $517.2M | $726.4M | $957.8M | $1.1B |
| Net income | −$216.0M | −$61.3M | $226.5M | $391.0M |
| Operating cash flow | −$114.0M | $16.7M | $157.7M | $109.8M |
| Free cash flow | −$114.0M | $16.7M | $157.2M | $105.1M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$1.1B ▲ 11.9% in FY2025$391.0M ▲ 72.7% in FY2025$105.1M ▼ 33.1% in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 5, 2026James Kihara (Senior Vice President, Finance) ended a 10b5-1 trading plan reported in the 10-Q, up to 41,421 shares, runs to Mar 9, 2027
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
-
8-KOct 23, 2026Director or officer change 8-K item 5.02
About the company
Acadia Pharmaceuticals Inc, San Diego, CA · from the 10-K filed Feb 26, 2026
We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP).
- Headquarters
- San Diego, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ACAD/export.csv") into a cell.